Molecular Research and Treatment of Urologic Cancer DOI Open Access
Hironobu Yamashita

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(24), С. 13666 - 13666

Опубликована: Дек. 20, 2024

Urologic cancers exhibit tumor heterogeneity in their morphology, gene expression, and phenotypic features, have different responses to drug treatment [...]

Язык: Английский

Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients DOI
Sukhad Kural, Abhay Kumar Pathak, Shweta Singh

и другие.

Annals of Surgical Oncology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 4, 2024

Язык: Английский

Процитировано

6

Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein DOI

Zeng-mi Mo,

Shasha Gai,

Xiaopeng Qin

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 140438 - 140438

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

DLEU2 facilitates bladder cancer progression through miR-103a-2-5p/SOS1 axis DOI Creative Commons
Yinlong Liu,

Jian Hu,

Baochun Liao

и другие.

PeerJ, Год журнала: 2025, Номер 13, С. e18995 - e18995

Опубликована: Апрель 8, 2025

Bladder cancer (BC) represents a life-threatening malignancy within the urinary system. Dysregulated long non-coding RNAs (lncRNAs) play pivotal roles in advancement of BC. LncRNA deleted lymphocytic leukemia 2 (DLEU2) is implicated development various cancers. However, its role and regulatory mechanisms BC remain unclear. This research aimed to explore expression, biological function, molecular DLEU2 In progression. Expression profiles lncRNAs, microRNAs (miRNAs), mRNAs normal tissues were examined by leveraging raw data sourced from NCBI GEO database. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) validated expression levels cells. To evaluate proliferation migration capabilities cells, assays such as CCK-8, EdU, Transwell, scratch carried out. Luciferase reporter interactions between miR-103a-2-5p with SOS1. Protein SOS1 cells was analyzed via western blotting. markedly increased tissues. Functionally, overexpression elevated cell migration, while knockdown produced opposite effects. Mechanistically, acted sponge for miR-103a-2-5p, which targeted enhanced co-knockdown reversed these Overexpression also promoted counteracted overexpression. Conversely, inhibited processes, reversing this inhibition. These findings demonstrate that facilitates progression miR-103a-2-5p/SOS1 axis. study reveals novel mechanism underlying highlights potential therapeutic target treatment.

Язык: Английский

Процитировано

0

Targeting the PI3K/AKT/mTOR Signaling Pathway in TCCSUP Bladder Cancer Cell by the Panax ginseng Leaf Extract Green‐Synthesized Silver Nanoparticles DOI

Hongxin Mu,

K Zhang,

Yaming Zhao

и другие.

Applied Organometallic Chemistry, Год журнала: 2025, Номер 39(6)

Опубликована: Май 21, 2025

ABSTRACT The mTOR signaling pathway has a main role in integrating extracellular and intracellular signals, acting as key regulator of proliferation, growth, metabolism, survival. Research conducted over the past 10 years revealed that is activated numerous cellular processes, including angiogenesis, tumor formation, adipogenesis, insulin resistance, T‐lymphocyte activation. Furthermore, it dysregulated various human diseases, type 2 diabetes cancer. Recently, nanoparticles (NPs) have been formulated for cancer treatment. Treatment several cancers such uterine cancer, lung gastric bone glioma reported by silver NPs green‐synthesized plant extracts. This study reports on green manufacture utilizing Panax ginseng its antibladder properties follow PI3K‐Akt‐mTOR pathway. were described using UV‐Vis, XRD, FE‐SEM, FT‐IR. biological aspects focus recent study. MTT examination was used to evaluate cytotoxic potentials Ag HUVEC TCCSUP cells after exposed them 48 h. with spherical shape an appropriate average size 43.71 nm shown crystallinity structure results. When NPs, cell's viability diminished, resulting IC 50 value 154 μg/mL. An in‐depth indicated influence apoptosis cell proliferation through modulation. Additionally, antioxidant evaluation showed NPs' regarding DPPH 62 inhibited cycle induced triggered NPs. Therefore, treatment bladder carcinoma, may prove be beneficial natural anticancer agent.

Язык: Английский

Процитировано

0

Cu-based hybrid nanozyme for AMPK activation and enhanced PD-1 checkpoint blockade in bladder cancer therapy DOI
Hai Cai,

P. Xue,

Yaxin Ma

и другие.

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 164343 - 164343

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0

Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects DOI Creative Commons
Mariana Pereira, Nuno Vale

Biomedicines, Год журнала: 2024, Номер 12(3), С. 647 - 647

Опубликована: Март 14, 2024

This research explores the therapeutic efficacy of Darunavir (DRV), Rilpivirine (RPV), and Etravirine (ETV) against UM-UC-5 bladder cancer cells, addressing critical need for innovative treatments in research. Through a comprehensive assessment their individual combined effects across diverse time intervals, ETV emerges as most potent drug, with lowest IC50 5.9 µM, closely followed by RPV (lowest 9.6 µM), while DRV exhibits least effectiveness 25.6 µM). Notably, significant synergistic effect is evident combination, especially at 48 72 h low concentrations. Synergies are also observed DRV, albeit to lesser extent primarily h. Conversely, combination yields minimal effects, predominantly additive nature. In summary, this pre-clinical investigation underscores promising potential RPV, both standalone hinting repurposing opportunities therapy, which could give new treatment method disease that faster without severe side anticancer drugs. These findings represent substantial stride advancing personalized medicine within will be further scrutinized forthcoming studies.

Язык: Английский

Процитировано

2

The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer DOI Creative Commons
Tatiana Cano Barbadilla, Martina Álvarez, Juan Daniel Prieto Cuadra

и другие.

Diagnostics, Год журнала: 2024, Номер 14(22), С. 2501 - 2501

Опубликована: Ноя. 8, 2024

Bladder cancer (BC) is a highly heterogeneous disease, presenting clinical challenges, particularly in predicting patient outcomes and selecting effective treatments. Molecular subtyping has emerged as an essential tool for understanding the biological diversity of BC; however, its implementation practice remains limited due to high costs complexity genomic techniques. This review examines role immunohistochemistry (IHC) surrogate marker molecular BC, highlighting potential bridge gap between advanced classifications routine application; Methods: We explore evolution taxonomic classification with particular focus on cytokeratin (KRT) expression patterns normal urothelium, which are key identifying basal luminal subtypes. Furthermore, we emphasise need consensus IHC markers reliably define these subtypes, facilitating wider standardised use. The also analyses application both muscle-invasive (MIBC) non-muscle-invasive bladder (NMIBC), attention less extensively studied NMIBC cases. discuss practical advantages subtyping, including cost effectiveness feasibility standard pathology laboratories, alongside ongoing challenges such requirement protocols external validation across diverse settings; Conclusions: While limitations, it offers viable alternative laboratories lacking access Further research required determine optimal combination markers, establish diagnostic algorithm, validate through large-scale trials. will ultimately enhance accuracy, guide treatment decisions, improve outcomes.

Язык: Английский

Процитировано

1

Psychological Impact of Bladder Cancer: Insights from 219 Patients and Caregivers in Indonesia Using DASS-21 (2019-2023) DOI
Wahjoe Djatisoesanto, Yufi Aulia Azmi, Ida Bagus Gde Tirta Yoga Yatindra

и другие.

Medical Science Monitor, Год журнала: 2024, Номер 30

Опубликована: Июль 5, 2024

BACKGROUND Bladder cancer (BC) is a common disease worldwide. Low survival rates and high recurrence lead to the risk of mental disorders. This study analyzed 219 patients with bladder using Indonesian Version 21-item Depression, Anxiety, Stress Scale (DASS-21) related factors. MATERIAL AND METHODS cross-sectional included diagnosed during 2019-2023 in referral hospital Indonesia. Data were collected questionnaire that assessed characteristics DASS-21 questionnaire. RESULTS Some caregivers experienced depression, stress, anxiety. The percentage who anxiety was higher than for (47.9% vs 45.7%). Statistical analysis showed age, income, marital status associated incidence depression (p=0.000, p=0.001, p=0.000, respectively), p=0.012, stress p=0.007, respectively). Routes patient admission (p=0.043, respectively) employment (p=0.005, Employment also (p=0.038, found routes among (p=0.036 CONCLUSIONS Monitoring providing support are needed prevent poor prognosis due psychological problems, including paying attention sociodemographic

Язык: Английский

Процитировано

0

CONTENT OF DOPAMINE, NORADRENALINE, SEROTONIN AND 5-HYDROXYINDOLACETIC ACID IN THE URINE OF PATIENTS WITH BLADDER CANCER DEPENDING ON THE PRESENCE OF DIABETES MELLITUS DOI Open Access
I. A. Goroshinskaya, И. В. Каплиева, E.M. Ataeva

и другие.

Современные проблемы науки и образования (Modern Problems of Science and Education), Год журнала: 2024, Номер №4 2024, С. 22 - 22

Опубликована: Янв. 1, 2024

СОДЕРЖАНИЕ ДОФАМИНА, НОРАДРЕНАЛИНА, СЕРОТОНИНА И 5-ОКСИИНДОЛУКСУСНОЙ КИСЛОТЫ В МОЧЕ БОЛЬНЫХ РАКОМ МОЧЕВОГО ПУЗЫРЯ ЗАВИСИМОСТИ ОТ НАЛИЧИЯ САХАРНОГО ДИАБЕТАГорошинская И.А

Язык: Русский

Процитировано

0

ASO Author Reflections: Reevaluating Muscle Invasion in Bladder Cancer: The Role of VI-RADS in Guiding Re-resections/ Re-stage TURBT DOI
Sukhad Kural, Lalit Kumar

Annals of Surgical Oncology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 11, 2024

Язык: Английский

Процитировано

0